

NEWS RELEASE



September 22, 2021

VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting

Kyoto, Japan, September 22, 2021 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the Child Neurology Society 50th Annual Meeting being held in Boston, Massachusetts from Sept 29 – Oct 2.

The poster presentation will be given by Vamshi Rao, MD, from the Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, and will be available for viewing on October 1st JST. To access the presentation, you will need to register (charged) at the following site. For more information, please visit the Child Neurology Society Annual Meeting website to view the full program:

<https://www.childneurologysociety.org/colleagues/network/cns-annual-meeting/>.

About VILTEPSO

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VILTEPSO received marketing authorization under the conditional early approval system in Japan in March 2020 and became commercially available in Japan in May of the same year. In the United States, it received accelerated approval from the US Food and Drug Administration (FDA) in August 2020 and has been marketed through NS Pharma, Inc.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit <https://www.nspharma.com>. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

FAX: +81-75-321-9128